Stocks and Investing
Stocks and Investing
Mon, June 12, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Uy Ear Reiterated (ARQT) at Strong Buy and Held Target at $57 on, Jun 12th, 2023
Uy Ear of Mizuho, Reiterated "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy and Held Target at $57 on, Jun 12th, 2023.
Uy has made no other calls on ARQT in the last 4 months.
There are 5 other peers that have a rating on ARQT. Out of the 5 peers that are also analyzing ARQT, 0 agree with Uy's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Uy
- Gregory Fraser of "Truist Securities" Maintained at Strong Buy with Decreased Target to $40 on, Friday, May 26th, 2023
- Serge Belanger of "Needham" Reiterated at Strong Buy and Held Target at $24 on, Wednesday, May 17th, 2023
- Jonathan Block of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $33 on, Thursday, May 11th, 2023
- Nigel Dally of "Morgan Stanley" Maintained at Buy with Decreased Target to $45 on, Wednesday, May 10th, 2023
- Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $50 on, Wednesday, March 1st, 2023
Contributing Sources